The Lancet SS-31 (Elamipretide) and Heart Failure: Mitochondrial Dysfunction in Cardiac Research

Lancet Insights | 2026-06-29 | 11 min read

Analysis of SS-31 (elamipretide) and its effects on mitochondrial dysfunction in heart failure, covering cardiolipin targeting, ATP production, cardiac protection, and clinical trial evidence.

SS-31: Targeting Mitochondria in Heart Failure

The Lancet has covered research on novel heart failure therapies, including mitochondria-targeted approaches. SS-31 (elamipretide) represents an innovative strategy addressing mitochondrial dysfunction, a central feature of heart failure pathophysiology. This analysis examines SS-31's mechanism, clinical evidence, and future directions.

SS-31 Mechanism of Action

Structure and Targeting

SS-31 (elamipretide) is a tetrapeptide with strategic design:

Sequence: D-Arg-Dmt-Lys-Phe-NH2

Key features:

  • Dmt (2',6'-dimethyltyrosine): Aromatic cationic moiety
  • Selective accumulation in mitochondria
  • High affinity for cardiolipin

Cardiolipin Binding

Cardiolipin is uniquely localised to the inner mitochondrial membrane:

  • Phospholipid essential for cristae structure
  • Binds electron transport chain complexes
  • Critical for ATP production
  • Damaged in heart failure

SS-31 binds to cardiolipin through:

  • Electrostatic interactions
  • Hydrophobic insertion
  • Structural stabilisation

Mitochondrial Effects

SS-31 improves mitochondrial function through:

#### Cristae Stabilisation

  • Maintains proper cristae structure
  • Prevents electron transport chain disruption
  • Preserves ATP production capacity
  • Protects against structural damage

#### Electron Transport Chain

  • Improves Complex I-IV activity
  • Enhances electron transfer
  • Reduces electron leak
  • Improves coupling efficiency

#### ROS Reduction

  • Decreases reactive oxygen species
  • Prevents oxidative damage
  • Protects mitochondrial DNA
  • Reduces apoptosis signalling

Heart Failure Pathophysiology

Mitochondrial Dysfunction in HF

Heart failure involves progressive mitochondrial impairment:

#### Energy Depletion

  • Reduced ATP production
  • Impaired cardiac contractility
  • Energy starvation
  • Contributes to progression

#### Structural Damage

  • Cristae disruption
  • Swollen mitochondria
  • Reduced cristae density
  • Impaired fission/fusion balance

#### Oxidative Stress

  • Increased ROS production
  • Mitochondrial DNA damage
  • Protein oxidation
  • Lipid peroxidation

Therapeutic Implications

Addressing mitochondrial dysfunction offers:

  • Target upstream mechanisms
  • Potential disease modification
  • Complementary to current therapies
  • Novel therapeutic approach

Clinical Evidence

Phase 2 Trials

Promising early results:

#### Phase 2A Study

  • Improved symptoms in HF patients
  • Enhanced exercise capacity
  • Improved mitochondrial markers
  • Supported Phase 2B development

#### Phase 2B EMBRACE-HF

  • Subcutaneous infusion study
  • Improved peak VO2 in HFpEF
  • Reduced NT-proBNP in some patients
  • Good safety profile

Phase 3 PROGRESS-HF

The pivotal trial did not meet primary endpoint:

  • 24-week subcutaneous treatment
  • Primary endpoint: Hierarchical composite
  • Numerical improvements observed
  • Subgroup analyses ongoing

Lessons Learned

Understanding trial outcomes:

  • Patient selection important
  • Optimal dosing under investigation
  • Biomarker-guided therapy?
  • Earlier intervention?

Other Clinical Applications

Mitochondrial Myopathy

SS-31 has shown benefit in primary mitochondrial disease:

  • FDA breakthrough therapy designation
  • Improved NMDAS scores
  • Enhanced 6-minute walk distance
  • Benefits in Barth syndrome

Other Potential Indications

Research exploring:

  • Acute kidney injury
  • Huntington's disease
  • Diabetic complications
  • Age-related macular degeneration

Research Applications

In Vitro Studies

Cardiac mitochondrial research:

  • Cardiomyocyte culture
  • Oxygen consumption rate (OCR)
  • ATP production measurement
  • Mitochondrial membrane potential
  • ROS detection

In Vivo Research

Animal model protocols:

  • Myocardial infarction models
  • Pressure overload HF
  • Diabetic cardiomyopathy
  • Aged heart models

Clinical Research Endpoints

Human study measures:

  • Exercise testing (VO2 max)
  • Echocardiography
  • Cardiac MRI
  • Biomarkers (NT-proBNP, troponin)
  • Quality of life measures

Quality Standards

Purity Requirements

SS-31 research requires:

  • HPLC purity ≥99.5%
  • Mass spectrometry verification
  • D-amino acid configuration
  • Accurate peptide content
  • Batch-specific COA documentation

Storage and Handling

SS-31 stability considerations:

  • Lyophilised: -20°C protected
  • Reconstituted: Use within 24 hours
  • Subcutaneous infusion: Prepared fresh
  • Stability data important

Combination Approaches

With Standard HF Therapy

Potential combinations:

  • SS-31 + beta-blockers
  • SS-31 + ACE inhibitors/ARNIs
  • SS-31 + SGLT2 inhibitors
  • Comprehensive mitochondrial support

With Other Mitochondrial Peptides

MOTS-c combinations:

  • SS-31: Structural protection
  • MOTS-c: Metabolic signalling
  • Complementary mechanisms
  • Under investigation

Future Directions

Optimising Development

Areas for improvement:

  • Patient selection biomarkers
  • Dosing optimisation
  • Combination therapy studies
  • Earlier intervention

Novel Formulations

Development ongoing:

  • Oral formulations
  • Long-acting preparations
  • Targeted delivery
  • Combination products

Broader Applications

Expanding research:

  • HFpEF specifically
  • Acute heart failure
  • Prevention populations
  • Other mitochondrial diseases

ZePeptide provides research-grade SS-31 with complete analytical documentation for mitochondrial cardiology research.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.

Research peptide catalogSupplier checklistMore peptide guides